Collaboration on lonodelestat in COVID-19-related ARDS
Shares of Swiss biotech firm Santhera Pharmaceuticals (SIX: SANN) were up 26.75% to 10.14 Swiss francs in early trading, after the company announced a COVID-19 related collaboration.
Santhera has joined forces with Cold Spring Harbor Laboratory (CSHL) to investigate lonodelestat (POL6014), a potent inhibitor of human neutrophil elastase (hNE), as a therapeutic intervention for COVID-19-related acute respiratory distress syndrome (ARDS), a frequent result of the novel coronavirus.
The company acquired rights to POL6014 in 2018 from fellow Swiss firm Polyphor, in a deal that involved an upfront payment of around $7 million plus additional cash payments of up to 121 million francs ($124 million) contingent on future development, regulatory and particularly sales milestones
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze